Study of Epithelial Growth Factor Receptor Mutations in Tumor Specimens and Blood Samples From Patients With Non-Small Cell Lung Cancer Enrolled on Clinical Trial CASE-2507
- Identify mutations in epidermal growth factor receptor (EGFR) in non-small cell lung
cancer specimens from clinical trial CASE-2507.
- Investigate EGFR DNA copy-number changes.
- Determine abnormalities of other pathways, such as the c-MET and PI3K pathways as
potential mechanisms of resistance.
OUTLINE: This is a multicenter study.
DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/
reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance
mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed
using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in
these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear
cells positive for epithelial cell adhesion molecule (EpCAM).
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Predictive value of T790M mutation status of the second biopsy (before maintenance therapy on CASE-2507) on progression-free survival (PFS)
At the time of the second biopsy or surgical procedures
Afshin Dowlati, MD
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
United States: Institutional Review Board
|Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center||Cleveland, Ohio 44106-5065|